1. St John Smith E. Advances in understanding nociception and neuropathic pain. J Neurol 2018; 265(2): 231-8.

2. Colvin LA. Chemotherapy-induced peripheral neuropathy: where are we now? Pain 2019; 160 Suppl 1(Suppl 1): S1-S10.

3. Schuler U, Heller S. Chemotherapy-induced peripheral neuropathy and neuropathic pain. Schmerz 2017; 31(4): 413-25.

4. Staff NP, Fehrenbacher JC, Caillaud M, Damaj MI, Segal RA, Rieger S. Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol 2020; 324: 113121.

5. Sisignano M, Baron R, Scholich K, Geisslinger G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat Rev Neurol 2014; 10(12): 694-707.

6. Fedder D, Patel H, Saadabadi A. Atomoxetine. 2021 Aug 6. In: StatPearls (Internet). Treasure Island [FL]: StatPearls Publishing; 2021 Jan–.

7. Kremer M, Salvat E, Muller A, Yalcin I, Barrot M. Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience 2016; 338: 183-206.

8. Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. Pharmacol Rep 2013; 65(6): 1611-21.

9. Bahari Z, Meftahi GH. Spinal alpha(2) -adrenoceptors and neuropathic pain modulation; therapeutic target. vBr J Pharmacol 2019; 176(14): 2366-81.

10. Hajhashemi V, Banafshe HR, Minaiyan M, Mesdaghinia A, Abed A. Antinociceptive effects of venlafaxine in a rat model of peripheral neuropathy: role of alpha2-adrenergic receptors. Eur J Pharmacol 2014; 738: 230-6

11. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309(13): 1359-67.

12. Levey AI, Qiu D, Zhao L, Hu WT, Duong DM, Higginbotham L, et al. A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain 2021; awab452

13. Barbaros MB, Can ÖD, Üçel Uİ, Turan Yücel N, Demir Özkay Ü. Antihyperalgesic Activity of Atomoxetine on Diabetes-Induced Neuropathic Pain: Contribution of Noradrenergic and Dopaminergic Systems. Molecules 2018; 23(8): 2072.

14. Naji-Esfahani H, Vaseghi G, Safaeian L, Pilehvarian AA, Abed A, Rafieian-Kopaei M. Gender differences in a mouse model of chemotherapy-induced neuropathic pain. Lab Anim 2016; 50(1): 15-20

15. Abed A, Khoshnoud MJ, Taghian M, Aliasgharzadeh M, Mesdaghinia A. Quetiapine reverses paclitaxel-induced neuropathic pain in mice: Role of alpha2- adrenergic receptors. Iran J Basic Med Sci 2017; 20(11): 1182-8.

16. Hou QX, Yu L, Tian SQ, Jiang CJ, Yang WJ, Wang ZJ. Neuroprotective effects of atomoxetine against traumatic spinal cord injury in rats. Iran J Basic Med Sci 2016; 19(3): 272-80.

17. Choi S, Yamada A, Kim W, Kim SK, Furue H. Noradrenergic inhibition of spinal hyperexcitation elicited by cutaneous cold stimuli in rats with oxaliplatin-induced allodynia: electrophysiological and behavioral assessments. J Physiol Sci 2017; 67(3): 431-8.

18. Finnerup NB. Neuropathic pain and spasticity: intricate consequences of spinal cord injury. Spinal Cord 2017; 55(12): 1046-50.

19. Shim HS, Bae C, Wang J, Lee KH, Hankerd KM, Kim HK, Chung JM, La JH. Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain. Mol Pain 2019; 15: 1744806919840098.

20. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010; 9(8): 807-19

21. Finnerup NB, Kuner R, Jensen TS. Neuropathic Pain: From Mechanisms to Treatment. Physiol Rev 2021; 101(1): 259-301.

22. Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. Br J Anaesth 2017; 119(4): 737-49

23. Xu L, Zhang Y, Huang Y. Advances in the Treatment of Neuropathic Pain. Adv Exp Med Biol 2016; 904: 117-29.

24. Bates D, Schultheis BC, Hanes MC, Jolly SM, Chakravarthy KV, Deer TR, et al. A Comprehensive Algorithm for Management of Neuropathic Pain. Pain Med 2019; 20(Suppl 1): S2-S12

25. Obata H. Analgesic Mechanisms of Antidepressants for Neuropathic Pain. Int J Mol Sci 2017; 18(11): 2483

26. [26] Kalkman HO, Feuerbach D. Antidepressant therapies inhibit inflammation and microglial M1-polarization. Pharmacol Ther 2016; 163: 82-93

27. Cottingham C, Ferryman CJ, Wang Q. alpha2 Adrenergic Receptor Trafficking as a Therapeutic Target in Antidepressant Drug Action. Prog Mol Biol Transl Sci 2015; 132: 207-2

28. Deng L, Lee WH, Xu Z, Makriyannis A, Hohmann AG. Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems. Pharmacol Res 2016; 114: 75-89.

29. Katsuyama S, Sato K, Yagi T, Kishikawa Y, Nakamura H. Effects of repeated milnacipran and fluvoxamine treatment on mechanical allodynia in a mouse paclitaxel-induced neuropathic pain model. Biomed Res 2013; 34(2): 105-11.

30. Lu Y, Zhang P, Zhang Q, Yang C, Qian Y, Suo J, et al. Duloxetine Attenuates Paclitaxel-Induced Peripheral Nerve Injury by Inhibiting p53-Related Pathways. J Pharmacol Exp Ther 2020; 373(3): 453-62.